Eovist Generic Name & Formulations
Gadoxetate disodium 181.43mg/mL (0.25mmol/mL); soln for IV inj; preservative-free.
Gadolinium-based contrast agent.
Single-dose vials (10mL, 15mL)—5
For use in MRI of the liver to detect and characterize lesions in patients with known or suspected focal liver disease.
Eovist Dosage and Administration
Adults and Children
Premature infants: not established. Give as IV bolus inj at a rate of ~2mL/sec. 0.1mL/kg (0.025mmol/kg); flush IV cannula with normal saline after inj. See full labeling re: imaging guidelines.
Eovist Boxed Warnings
Nephrogenic systemic fibrosis.
Increased risk of nephrogenic systemic fibrosis in chronic kidney disease or acute kidney injury; avoid use. Screen for renal dysfunction. Do not exceed recommended dose and allow sufficient time for drug elimination before re-administration. Have emergency resuscitative equipment available. History of asthma or other allergic disorders. Monitor for signs/symptoms of hypersensitivity reactions during and after administration. Increased risk of gadolinium retention with multiple lifetime doses, in pregnant patients, children, and those with inflammatory conditions; minimize repetitive imaging studies. Elevated bilirubin (>3mg/dL) or ferritin may reduce hepatic contrast effect; perform MRI no later than 60mins following administration. Avoid extravasation. Severe renal or hepatic failure. Elderly. Pregnancy. Nursing mothers: consider interrupting nursing and pumping/discarding breast milk for up to 10hrs after inj.
Serum iron using complexometric methods may result in falsely high or low values for up to 24hrs.
Eovist Adverse Reactions
Nausea, headache, feeling hot, dizziness, back pain; hypersensitivity reactions.
Eovist Clinical Trials
Eovist Patient Counseling